CompletedNot Applicable

Genomics Used to Improve DEpression Decisions

United States1,398 participantsStarted 2014-04

Plain-language summary

Evaluate the impact of GeneSight Psychotropic on response to psychotropic treatment as judged by the mean change in the 17-item Hamilton Depression (HAM-D17) score from baseline to end of Week 8 of the study.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Delirium
✕. Dementia
✕. Amnestic and other cognitive disorder
✕. Schizophrenia or other psychotic disorder;

What they're measuring

Percent Change in the 17-item Hamilton Depression (HAM-D17) Score From Baseline to 8 Weeks

Timeframe: from baseline to end of Week 8

Trial details

NCT IDNCT02109939

SponsorAssurex Health Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2017-04-20

Results submitted2019-10-14

View on ClinicalTrials.gov More Major Depressive Disorder (MDD) trials